{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["angiogenesis", "anti-angiogenic", "anti-metastatic", "invasion", "metastasis", "migration", "oridonin"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33546106", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "08"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "02", "Day": "03"}], "Language": ["eng"], "ELocationID": ["775", "10.3390/molecules26040775"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "4", "PubDate": {"Year": "2021", "Month": "Feb", "Day": "03"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential.", "Abstract": {"AbstractText": ["Cancer is one of the leading causes of death worldwide, with a mortality rate of more than 9 million deaths reported in 2018. Conventional anti-cancer therapy can greatly improve survival however treatment resistance is still a major problem especially in metastatic disease. Targeted anti-cancer therapy is increasingly used with conventional therapy to improve patients' outcomes in advanced and metastatic tumors. However, due to the complexity of cancer biology and metastasis, it is urgent to develop new agents and evaluate the anti-cancer efficacy of available treatments. Many phytochemicals from medicinal plants have been reported to possess anti-cancer properties. One such compound is known as oridonin, a bioactive component of <i>Rabdosia rubescens</i>. Several studies have demonstrated that oridonin inhibits angiogenesis in various types of cancer, including breast, pancreatic, lung, colon and skin cancer. Oridonin's anti-cancer effects are mediated through the modulation of several signaling pathways which include upregulation of oncogenes and pro-angiogenic growth factors. Furthermore, oridonin also inhibits cell migration, invasion and metastasis via suppressing epithelial-to-mesenchymal transition and blocking downstream signaling targets in the cancer metastasis process. This review summarizes the recent applications of oridonin as an anti-angiogenic and anti-metastatic drug both in vitro and in vivo, and its potential mechanisms of action."]}, "AuthorList": [{"Identifier": ["0000-0001-5161-9194"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia."}], "LastName": "Abdullah", "ForeName": "Nurul Akmaryanti", "Initials": "NA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia."}], "LastName": "Md Hashim", "ForeName": "Nur Fariesha", "Initials": "NF"}, {"Identifier": ["0000-0002-0375-062X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wolfson Wohl Translational Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow City G61 1BD, UK."}], "LastName": "Ammar", "ForeName": "Aula", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia."}], "LastName": "Muhamad Zakuan", "ForeName": "Noraina", "Initials": "N"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Angiogenesis Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "Diterpenes, Kaurane"}, {"RegistryNumber": "0APJ98UCLQ", "NameOfSubstance": "oridonin"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Angiogenesis Inhibitors"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Diterpenes, Kaurane"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Isodon"}, {"QualifierName": ["blood supply", "drug therapy", "metabolism"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Dillek\u00e5s H., Rogers M.S., Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8:5574\u20135576. doi: 10.1002/cam4.2474.", "ArticleIdList": ["10.1002/cam4.2474", "PMC6745820", "31397113"]}, {"Citation": "American Cancer Society . Cancer Facts and Figures. American Cancer Society (ACS); Atlanta, GA, USA: 2020.", "ArticleIdList": ["PMC7848816", "33532112"]}, {"Citation": "Lambert A.W., Pattabiraman D.R., Weinberg R.A. Emerging biological principles of metastasis. Cell. 2017;168:670\u2013691. doi: 10.1016/j.cell.2016.11.037.", "ArticleIdList": ["10.1016/j.cell.2016.11.037", "PMC5308465", "28187288"]}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Rivera E., Gomez H. Proceedings of the Breast Cancer Research. Volume 12. Springer; Berlin/Heidelberg, Germany: 2010. Chemotherapy resistance in metastatic breast cancer: The evolving role of ixabepilone; p. S2.", "ArticleIdList": ["PMC2972556", "21050423"]}, {"Citation": "Luo H., Vong C.T., Chen H., Gao Y., Lyu P., Qiu L., Zhao M., Liu Q., Cheng Z., Zou J., et al. Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine. Chin. Med. 2019:14. doi: 10.1186/s13020-019-0270-9.", "ArticleIdList": ["10.1186/s13020-019-0270-9", "PMC6836491", "31719837"]}, {"Citation": "Chen S., Liu J., Zhang H. Efficacy of rabdosia rubescens in the treatment of gingivitis. J. Huazhong Univ. Sci. Technol. Med. Sci. 2009;29:659. doi: 10.1007/s11596-009-0525-2.", "ArticleIdList": ["10.1007/s11596-009-0525-2", "19821105"]}, {"Citation": "Peng M., Liu B., Mao M. Study on the Application of Chinese Patent Drug and Chinese Formula of Rabdosia Rubescens. IOP Conf. Ser. Mater. Sci. Eng. 2018;301:12060. doi: 10.1088/1757-899X/301/1/012060.", "ArticleIdList": ["10.1088/1757-899X/301/1/012060"]}, {"Citation": "Fujita E., Fujita T., Shibuya M. Diterpenoid constituents of Isodon trichocarpus and Isodon japonicus (terpenoids IV) Tetrahedron Lett. 1966;7:3153\u20133162. doi: 10.1016/S0040-4039(01)99930-7.", "ArticleIdList": ["10.1016/S0040-4039(01)99930-7"]}, {"Citation": "Wang S., Yu L., Yang H., Li C., Hui Z., Xu Y., Zhu X. Oridonin attenuates synaptic loss and cognitive deficits in an A\u03b21\u201342-induced mouse model of Alzheimer\u2019s disease. PLoS ONE. 2016;11:e0151397. doi: 10.1371/journal.pone.0151397.", "ArticleIdList": ["10.1371/journal.pone.0151397", "PMC4790895", "26974541"]}, {"Citation": "He H., Jiang H., Chen Y., Ye J., Wang A., Wang C., Liu Q., Liang G., Deng X., Jiang W. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 2018;9:1\u201312. doi: 10.1038/s41467-018-04947-6.", "ArticleIdList": ["10.1038/s41467-018-04947-6", "PMC6026158", "29959312"]}, {"Citation": "Yuan Z., Ouyang P., Gu K., Rehman T., Zhang T., Yin Z., Fu H., Lin J., He C., Shu G. The antibacterial mechanism of oridonin against methicillin-resistant Staphylococcus aureus (MRSA) Pharm. Biol. 2019;57:710\u2013716. doi: 10.1080/13880209.2019.1674342.", "ArticleIdList": ["10.1080/13880209.2019.1674342", "PMC8871620", "31622118"]}, {"Citation": "Wang S., Zhong Z., Wan J., Tan W., Wu G., Chen M., Wang Y. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am. J. Chin. Med. 2013;41:177\u2013196. doi: 10.1142/S0192415X13500134.", "ArticleIdList": ["10.1142/S0192415X13500134", "23336515"]}, {"Citation": "Yao Z., Xie F., Li M., Liang Z., Xu W., Yang J., Liu C., Li H., Zhou H., Qu L.-H. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 2017;8 doi: 10.1038/cddis.2017.35.", "ArticleIdList": ["10.1038/cddis.2017.35", "PMC5386482", "28230866"]}, {"Citation": "Wang B., Shen C., Li Y., Zhang T., Huang H., Ren J., Hu Z., Xu J., Xu B. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. OncoTargets Ther. 2019;12:5751\u20135765. doi: 10.2147/OTT.S208924.", "ArticleIdList": ["10.2147/OTT.S208924", "PMC6645696", "31410021"]}, {"Citation": "Xu L., Bi Y., Xu Y., Zhang Z., Xu W., Zhang S., Chen J. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J. Cell. Mol. Med. 2020;24:4480\u20134493. doi: 10.1111/jcmm.15106.", "ArticleIdList": ["10.1111/jcmm.15106", "PMC7176879", "32168416"]}, {"Citation": "Ren D.-L., Ghoorun R.A., Wu X.-H., Chen H.-L., Zhou Q., Wu X.-B. Oridonin induces apoptosis in HGC-27 cells by activating the JNK signaling pathway. Oncol. Lett. 2020;19:255\u2013260. doi: 10.3892/ol.2019.11104.", "ArticleIdList": ["10.3892/ol.2019.11104", "PMC6923929", "31897137"]}, {"Citation": "Lu J., Chen X., Qu S., Yao B., Xu Y., Wu J., Jin Y., Ma C. Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol. Lett. 2017;13:2838\u20132846. doi: 10.3892/ol.2017.5751.", "ArticleIdList": ["10.3892/ol.2017.5751", "PMC5403405", "28454475"]}, {"Citation": "Ren K.-K., Wang H.-Z., Xie L.-P., Chen D.-W., Liu X., Sun J., Nie Y.-C., Zhang R.-Q. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J. Ethnopharmacol. 2006;103:176\u2013180. doi: 10.1016/j.jep.2005.07.020.", "ArticleIdList": ["10.1016/j.jep.2005.07.020", "16169170"]}, {"Citation": "Nagy J.A., Dvorak H.F. Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets. Clin. Exp. Metastasis. 2012;29:657\u2013662. doi: 10.1007/s10585-012-9500-6.", "ArticleIdList": ["10.1007/s10585-012-9500-6", "PMC3484269", "22692562"]}, {"Citation": "Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020;77:1745\u20131770. doi: 10.1007/s00018-019-03351-7.", "ArticleIdList": ["10.1007/s00018-019-03351-7", "PMC7190605", "31690961"]}, {"Citation": "Nasir A. Predictive Biomarkers in Oncology. Springer; Cham, Switzerland: 2019. Angiogenic signaling pathways and anti-angiogenic therapies in human cancer; pp. 243\u2013262."}, {"Citation": "Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 2003;3:401\u2013410. doi: 10.1038/nrc1093.", "ArticleIdList": ["10.1038/nrc1093", "12778130"]}, {"Citation": "Almog N., Ma L., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009;69:836\u2013844. doi: 10.1158/0008-5472.CAN-08-2590.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-2590", "19176381"]}, {"Citation": "Zuazo-Gaztelu I., Casanovas O. Unraveling the role of angiogenesis in cancer ecosystems. Front. Oncol. 2018;8:248. doi: 10.3389/fonc.2018.00248.", "ArticleIdList": ["10.3389/fonc.2018.00248", "PMC6036108", "30013950"]}, {"Citation": "Isogai S., Lawson N.D., Torrealday S., Horiguchi M., Weinstein B.M. Angiogenic network formation in the developing vertebrate trunk. Development. 2003;130:5281\u20135290. doi: 10.1242/dev.00733.", "ArticleIdList": ["10.1242/dev.00733", "12954720"]}, {"Citation": "Zecchin A., Kalucka J., Dubois C., Carmeliet P. How endothelial cells adapt their metabolism to form vessels in tumors. Front. Immunol. 2017;8:1750. doi: 10.3389/fimmu.2017.01750.", "ArticleIdList": ["10.3389/fimmu.2017.01750", "PMC5732229", "29321777"]}, {"Citation": "Shawber C.J., Kitajewski J. Notch function in the vasculature: Insights from zebrafish, mouse and man. Bioessays. 2004;26:225\u2013234. doi: 10.1002/bies.20004.", "ArticleIdList": ["10.1002/bies.20004", "14988924"]}, {"Citation": "Qiao L., Liang N., Zhang J., Xie J., Liu F., Xu D., Yu X., Tian Y. Advanced research on vasculogenic mimicry in cancer. J. Cell. Mol. Med. 2015;19:315\u2013326. doi: 10.1111/jcmm.12496.", "ArticleIdList": ["10.1111/jcmm.12496", "PMC4407602", "25598425"]}, {"Citation": "Tewari K.S., Sill M.W., Long H.J., III, Penson R.T., Huang H., Ramondetta L.M., Landrum L.M., Oaknin A., Reid T.J., Leitao M.M. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 2014;370:734\u2013743. doi: 10.1056/NEJMoa1309748.", "ArticleIdList": ["10.1056/NEJMoa1309748", "PMC4010094", "24552320"]}, {"Citation": "Finke J., Ko J., Rini B., Rayman P., Ireland J., Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 2011;11:856\u2013861. doi: 10.1016/j.intimp.2011.01.030.", "ArticleIdList": ["10.1016/j.intimp.2011.01.030", "PMC3109226", "21315783"]}, {"Citation": "Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti-and pro-angiogenic therapies. Genes Cancer. 2011;2:1097\u20131105. doi: 10.1177/1947601911423031.", "ArticleIdList": ["10.1177/1947601911423031", "PMC3411125", "22866201"]}, {"Citation": "Sa\u2011Nguanraksa D., Chuangsuwanich T., Pongpruttipan T. High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer. Mol. Clin. Oncol. 2015;3:1103\u20131108. doi: 10.3892/mco.2015.574.", "ArticleIdList": ["10.3892/mco.2015.574", "PMC4534845", "26623059"]}, {"Citation": "George D.J., Halabi S., Shepard T.F., Vogelzang N.J., Hayes D.F., Small E.J., Kantoff P.W. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 2001;7:1932\u20131936.", "ArticleIdList": ["11448906"]}, {"Citation": "Horikawa N., Abiko K., Matsumura N., Hamanishi J., Baba T., Yamaguchi K., Yoshioka Y., Koshiyama M., Konishi I. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin. Cancer Res. 2017;23:587\u2013599. doi: 10.1158/1078-0432.CCR-16-0387.", "ArticleIdList": ["10.1158/1078-0432.CCR-16-0387", "27401249"]}, {"Citation": "Zanotelli M.R., Reinhart-King C.A. Biomechanics in Oncology. Springer; New York, NY, USA: 2018. Mechanical forces in tumor angiogenesis; pp. 91\u2013112.", "ArticleIdList": ["PMC6986816", "30368750"]}, {"Citation": "Dong Y., Zhang T., Li J., Deng H., Song Y., Zhai D., Peng Y., Lu X., Liu M., Zhao Y., et al. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the notch signaling. PLoS ONE. 2014:9. doi: 10.1371/journal.pone.0113830.", "ArticleIdList": ["10.1371/journal.pone.0113830", "PMC4259472", "25485753"]}, {"Citation": "Jiang J.-H., Pi J., Cai J.-Y. Oridonin exhibits anti-angiogenic activity in human umbilical vein endothelial cells by inhibiting VEGF-induced VEGFR-2 signaling pathway. Pathol. Res. Pract. 2020;216:153031. doi: 10.1016/j.prp.2020.153031.", "ArticleIdList": ["10.1016/j.prp.2020.153031", "32703495"]}, {"Citation": "Tian L., Xie K., Sheng D., Wan X., Zhu G. Antiangiogenic effects of oridonin. BMC Complement. Altern. Med. 2017;17 doi: 10.1186/s12906-017-1706-3.", "ArticleIdList": ["10.1186/s12906-017-1706-3", "PMC5379751", "28376864"]}, {"Citation": "Li C., Wang Q., Shen S., Wei X., Li G. Oridonin inhibits vegf-a-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo. Oncol. Lett. 2018;16:2289\u20132298. doi: 10.3892/ol.2018.8943.", "ArticleIdList": ["10.3892/ol.2018.8943", "PMC6036431", "30008931"]}, {"Citation": "Xia S., Zhang X., Li C., Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm. J. 2017;25:638\u2013643. doi: 10.1016/j.jsps.2017.04.037.", "ArticleIdList": ["10.1016/j.jsps.2017.04.037", "PMC5447451", "28579904"]}, {"Citation": "Karar J., Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 2011;4:51. doi: 10.3389/fnmol.2011.00051.", "ArticleIdList": ["10.3389/fnmol.2011.00051", "PMC3228996", "22144946"]}, {"Citation": "Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I., Witteveen P., Bamias A. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Obstet. Gynecol. Surv. 2014;69:402\u2013404. doi: 10.1097/01.ogx.0000452705.82050.e4.", "ArticleIdList": ["10.1097/01.ogx.0000452705.82050.e4", "24637997"]}, {"Citation": "Li J., Wu Y., Wang D., Zou L., Fu C., Zhang J., Leung G.P.-H. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. Pharmacol. Res. 2019;146 doi: 10.1016/j.phrs.2019.104313.", "ArticleIdList": ["10.1016/j.phrs.2019.104313", "31202781"]}, {"Citation": "Steeg P.S. Targeting metastasis. Nat. Rev. Cancer. 2016;16:201. doi: 10.1038/nrc.2016.25.", "ArticleIdList": ["10.1038/nrc.2016.25", "PMC7055530", "27009393"]}, {"Citation": "Thiery J.P. Epithelial\u2013mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2002;2:442\u2013454. doi: 10.1038/nrc822.", "ArticleIdList": ["10.1038/nrc822", "12189386"]}, {"Citation": "De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer. 2013;13:97\u2013110. doi: 10.1038/nrc3447.", "ArticleIdList": ["10.1038/nrc3447", "23344542"]}, {"Citation": "Wu S., Du Y., Beckford J., Alachkar H. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. J. Transl. Med. 2018;16:1\u20139. doi: 10.1186/s12967-018-1539-y.", "ArticleIdList": ["10.1186/s12967-018-1539-y", "PMC6009962", "29925392"]}, {"Citation": "Mendez M.G., Kojima S., Goldman R.D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24:1838\u20131851. doi: 10.1096/fj.09-151639.", "ArticleIdList": ["10.1096/fj.09-151639", "PMC2874471", "20097873"]}, {"Citation": "Hsiao C.-T., Cheng H.-W., Huang C.-M., Li H.-R., Ou M.-H., Huang J.-R., Khoo K.-H., Yu H.W., Chen Y.-Q., Wang Y.-K. Fibronectin in cell adhesion and migration via N-glycosylation. Oncotarget. 2017;8:70653. doi: 10.18632/oncotarget.19969.", "ArticleIdList": ["10.18632/oncotarget.19969", "PMC5642584", "29050309"]}, {"Citation": "Santamaria P.G., Moreno-Bueno G., Portillo F., Cano A. EMT: Present and future in clinical oncology. Mol. Oncol. 2017;11:718\u2013738. doi: 10.1002/1878-0261.12091.", "ArticleIdList": ["10.1002/1878-0261.12091", "PMC5496494", "28590039"]}, {"Citation": "Gui Z., Luo F., Yang Y., Shen C., Li S., Xu J. Oridonin inhibition and miR-200b-3p/ZEB1 axis in human pancreatic cancer. Int. J. Oncol. 2017;50:111\u2013120. doi: 10.3892/ijo.2016.3772.", "ArticleIdList": ["10.3892/ijo.2016.3772", "27878247"]}, {"Citation": "Lou S., Xu J., Wang B., Li S., Ren J., Hu Z., Xu B., Luo F. Downregulation of lncRNA AFAP1-AS1 by oridonin inhibits the epithelial-to-mesenchymal transition and proliferation of pancreatic cancer cells. Acta Biochim. Biophys. Sin. 2018;51:814\u2013825. doi: 10.1093/abbs/gmz071.", "ArticleIdList": ["10.1093/abbs/gmz071", "31314060"]}, {"Citation": "Sun Y., Jiang X., Lu Y., Zhu J., Yu L., Ma B., Zhang Q. Oridonin prevents epithelial-mesenchymal transition and TGF-\u03b21-induced epithelial-mesenchymal transition by inhibiting TGF-\u03b21/Smad2/3 in osteosarcoma. Chem. Biol. Interact. 2018;296:57\u201364. doi: 10.1016/j.cbi.2018.09.013.", "ArticleIdList": ["10.1016/j.cbi.2018.09.013", "30243739"]}, {"Citation": "Wieczorek E., Jablonska E., Wasowicz W., Reszka E. Matrix metalloproteinases and genetic mouse models in cancer research: A mini-review. Tumor Biol. 2015;36:163\u2013175. doi: 10.1007/s13277-014-2747-6.", "ArticleIdList": ["10.1007/s13277-014-2747-6", "PMC4315474", "25352026"]}, {"Citation": "Smith B.N., Bhowmick N.A. Role of EMT in metastasis and therapy resistance. J. Clin. Med. 2016;5:17. doi: 10.3390/jcm5020017.", "ArticleIdList": ["10.3390/jcm5020017", "PMC4773773", "26828526"]}, {"Citation": "Ma S., Tan W., Du B., Liu W., Li W., Che D., Zhang G. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Mol. Med. Rep. 2016;13:3342\u20133348. doi: 10.3892/mmr.2016.4897.", "ArticleIdList": ["10.3892/mmr.2016.4897", "26935490"]}, {"Citation": "Zhang J., Yan S., Tao Z., Wang C., Huang M., Zhang X., Du Y. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway. J. BU ON. 2019;24:1175\u20131180.", "ArticleIdList": ["31424676"]}, {"Citation": "Zhang Y., Wang L., Zi Y., Zhang L., Guo Y., Huang Y. Oridonin effectively reverses the drug resistance of cisplatin involving induction of cell apoptosis and inhibition of MMP expression in human acute myeloid leukemia cells. Saudi J. Biol. Sci. 2017;24:678\u2013686. doi: 10.1016/j.sjbs.2017.01.042.", "ArticleIdList": ["10.1016/j.sjbs.2017.01.042", "PMC5372424", "28386196"]}, {"Citation": "Xiao X., He Z., Cao W., Cai F., Zhang L., Huang Q., Fan C., Duan C., Wang X., Wang J., et al. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int. J. Oncol. 2016;48:2608\u20132618. doi: 10.3892/ijo.2016.3488.", "ArticleIdList": ["10.3892/ijo.2016.3488", "27082429"]}, {"Citation": "Liu Q.-Q., Chen K., Ye Q., Jiang X.-H., Sun Y.-W. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/\u03b2-catenin signaling pathway. Cancer Cell Int. 2016;16 doi: 10.1186/s12935-016-0336-z.", "ArticleIdList": ["10.1186/s12935-016-0336-z", "PMC4957915", "27453691"]}, {"Citation": "Zhang Y., Zhang X., Ye M., Jing P., Xiong J., Han Z., Kong J., Li M., Lai X., Chang N., et al. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. Cancer Lett. 2018;419:75\u201383. doi: 10.1016/j.canlet.2018.01.047.", "ArticleIdList": ["10.1016/j.canlet.2018.01.047", "29355657"]}, {"Citation": "Winkler J., Abisoye-Ogunniyan A., Metcalf K.J., Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 2020;11:1\u201319.", "ArticleIdList": ["PMC7547708", "33037194"]}, {"Citation": "Chiang S.P.H., Cabrera R.M., Segall J.E. Tumor cell intravasation. Am. J. Physiol. Physiol. 2016;311:C1\u2013C14. doi: 10.1152/ajpcell.00238.2015.", "ArticleIdList": ["10.1152/ajpcell.00238.2015", "PMC4967137", "27076614"]}, {"Citation": "Fontebasso Y., Dubinett S.M. Drug development for metastasis prevention. Crit. Rev. Oncog. 2015;20:449\u2013473. doi: 10.1615/CritRevOncog.v20.i5-6.150.", "ArticleIdList": ["10.1615/CritRevOncog.v20.i5-6.150", "PMC6497172", "27279241"]}, {"Citation": "Fares J., Fares M.Y., Khachfe H.H., Salhab H.A., Fares Y. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct. Target. Ther. 2020;5:1\u201317. doi: 10.1038/s41392-020-0134-x.", "ArticleIdList": ["10.1038/s41392-020-0134-x", "PMC7067809", "32296047"]}, {"Citation": "Valastyan S., Weinberg R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell. 2011;147:275\u2013292. doi: 10.1016/j.cell.2011.09.024.", "ArticleIdList": ["10.1016/j.cell.2011.09.024", "PMC3261217", "22000009"]}, {"Citation": "Vandenbroucke R.E., Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 2014;13:904\u2013927. doi: 10.1038/nrd4390.", "ArticleIdList": ["10.1038/nrd4390", "25376097"]}, {"Citation": "Teixeira A.F., Dijke P.T., Zhu H.-J. On-Target Anti-TGF-\u03b2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges? Front. Cell Dev. Biol. 2020;8:605. doi: 10.3389/fcell.2020.00605.", "ArticleIdList": ["10.3389/fcell.2020.00605", "PMC7360684", "32733895"]}, {"Citation": "Bu H.-Q., Shen F., Cui J. The inhibitory effect of oridonin on colon cancer was mediated by deactivation of TGF-\u03b21/smads-pai-1 signaling pathway in vitro and vivo. OncoTargets Ther. 2019;12:7467\u20137476. doi: 10.2147/OTT.S220401.", "ArticleIdList": ["10.2147/OTT.S220401", "PMC6752205", "31686852"]}, {"Citation": "Xia R., Chen S.-X., Qin Q., Chen Y., Zhang W.-W., Zhu R.R., Deng A.-M. Oridonin suppresses proliferation of human ovarian cancer cells via blockage of mTOR signaling. Asian Pac. J. Cancer Prev. 2016;17:667\u2013671. doi: 10.7314/APJCP.2016.17.2.667.", "ArticleIdList": ["10.7314/APJCP.2016.17.2.667", "26925661"]}, {"Citation": "Bi E., Liu D., Li Y., Mao X., Wang A., Wang J. Oridonin induces growth inhibition and apoptosis in human gastric carcinoma cells by enhancement of p53 expression and function. Braz. J. Med. Biol. Res. 2018;51 doi: 10.1590/1414-431x20187599.", "ArticleIdList": ["10.1590/1414-431x20187599", "PMC6247279", "30462771"]}, {"Citation": "Xu S., Yang S., Sun G., Huang W., Zhang Y. Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma. DNA Cell Biol. 2014;33:802\u2013806. doi: 10.1089/dna.2014.2527.", "ArticleIdList": ["10.1089/dna.2014.2527", "25098449"]}, {"Citation": "Ahel J., Hudorovi\u0107 N., Vi\u010di\u0107-Hudorovi\u0107 V., Nikles H. Tgf-Beta in the Natural History of Prostate Cancer. Acta Clin. Croat. 2019;58:128\u2013138. doi: 10.20471/acc.2019.58.01.17.", "ArticleIdList": ["10.20471/acc.2019.58.01.17", "PMC6629207", "31363335"]}, {"Citation": "Yang L. TGF\u03b2 and cancer metastasis: An inflammation link. Cancer Metastasis Rev. 2010;29:263\u2013271. doi: 10.1007/s10555-010-9226-3.", "ArticleIdList": ["10.1007/s10555-010-9226-3", "PMC6640647", "20437081"]}, {"Citation": "Margadant C., Sonnenberg A. Integrin\u2013TGF-\u03b2 crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97\u2013105. doi: 10.1038/embor.2009.276.", "ArticleIdList": ["10.1038/embor.2009.276", "PMC2828749", "20075988"]}, {"Citation": "Sarwar M.D., Xia Y.-X., Liang Z.-M., Tsang S.W., Zhang H.-J. Mechanistic pathways and molecular targets of plant-derived anticancer ent-kaurane diterpenes. Biomolecules. 2020;10:144. doi: 10.3390/biom10010144.", "ArticleIdList": ["10.3390/biom10010144", "PMC7023344", "31963204"]}, {"Citation": "Li C.-Y., Wang Q., Shen S., Wei X.-L., Li G.-X. Oridonin inhibits migration, invasion, adhesion and TGF-\u00df1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/AKT/GSK-3\u00df signaling pathway. Oncol. Lett. 2018;15:1362\u20131372. doi: 10.3892/ol.2017.7421.", "ArticleIdList": ["10.3892/ol.2017.7421", "PMC5772702", "29399187"]}, {"Citation": "Guo J., Chen T., Ma Z., Qiao C., Yuan F., Guo X., Liu J., Shen Y., Yu L., Xiang A. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-\u03b2 receptor. Int. Immunopharmacol. 2020;88:106831. doi: 10.1016/j.intimp.2020.106831.", "ArticleIdList": ["10.1016/j.intimp.2020.106831", "32853925"]}, {"Citation": "Park H.S., Jang M.H., Kim E.J., Kim H.J., Lee H.J., Kim Y.J., Kim J.H., Kang E., Kim S.-W., Kim I.A. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 2014;27:1212\u20131222. doi: 10.1038/modpathol.2013.251.", "ArticleIdList": ["10.1038/modpathol.2013.251", "24406864"]}, {"Citation": "Wang K., Li D., Sun L. High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. OncoTargets Ther. 2016;9:377. doi: 10.2147/OTT.S96309.", "ArticleIdList": ["10.2147/OTT.S96309", "PMC4727521", "26855586"]}, {"Citation": "Hsieh C.-Y., Tsai P.-C., Tseng C.-H., Chen Y., Chang L.-S., Lin S.-R. Inhibition of EGF/EGFR activation with naphtho [1, 2-b] furan-4, 5-dione blocks migration and invasion of MDA-MB-231 cells. Toxicol. In Vitro. 2013;27:1\u201310. doi: 10.1016/j.tiv.2012.10.001.", "ArticleIdList": ["10.1016/j.tiv.2012.10.001", "23064031"]}, {"Citation": "Guo Y., Pan W., Liu S., Shen Z., Xu Y., Hu L. ERK/MAPK signalling pathway and tumorigenesis. Exp. Ther. Med. 2020;19:1997\u20132007. doi: 10.3892/etm.2020.8454.", "ArticleIdList": ["10.3892/etm.2020.8454", "PMC7027163", "32104259"]}, {"Citation": "Jackson J.L., Young M.R.I. Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin. Exp. Metastasis. 2003;20:357\u2013364. doi: 10.1023/A:1024012000009.", "ArticleIdList": ["10.1023/A:1024012000009", "12856723"]}, {"Citation": "Benefield J., Meisinger J., Petruzzelli G.J., Young M.R. Endothelial cell response to human head and neck squamous cell carcinomas involves downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and increased motility. Invasion Metastasis. 1997;17:210\u2013220.", "ArticleIdList": ["9778593"]}, {"Citation": "Zhang J., Hochwald S.N. The role of FAK in tumor metabolism and therapy. Pharmacol. Ther. 2014;142:154\u2013163. doi: 10.1016/j.pharmthera.2013.12.003.", "ArticleIdList": ["10.1016/j.pharmthera.2013.12.003", "PMC6349254", "24333503"]}, {"Citation": "Schmidt A., Kunz J., Hall M.N. TOR2 is required for organization of the actin cytoskeleton in yeast. Proc. Natl. Acad. Sci. USA. 1996;93:13780\u201313785. doi: 10.1073/pnas.93.24.13780.", "ArticleIdList": ["10.1073/pnas.93.24.13780", "PMC19424", "8943012"]}, {"Citation": "Dada S., Demartines N., Dormond O. mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem. Biophys. Res. Commun. 2008;372:875\u2013879. doi: 10.1016/j.bbrc.2008.05.154.", "ArticleIdList": ["10.1016/j.bbrc.2008.05.154", "18539142"]}, {"Citation": "Wang Y., Zhu Z. Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway. Arch. Med. Sci. 2019;15:1017\u20131027. doi: 10.5114/aoms.2018.77068.", "ArticleIdList": ["10.5114/aoms.2018.77068", "PMC6657258", "31360196"]}, {"Citation": "Lu L., Barbi J., Pan F. The regulation of immune tolerance by FOXP3. Nat. Rev. Immunol. 2017;17:703. doi: 10.1038/nri.2017.75.", "ArticleIdList": ["10.1038/nri.2017.75", "PMC5793224", "28757603"]}, {"Citation": "Zhang C., Xu Y., Hao Q., Wang S., Li H., Li J., Gao Y., Li M., Li W., Xue X. FOXP 3 suppresses breast cancer metastasis through downregulation of CD 44. Int. J. Cancer. 2015;137:1279\u20131290. doi: 10.1002/ijc.29482.", "ArticleIdList": ["10.1002/ijc.29482", "25683728"]}, {"Citation": "Yang H., Gao Y., Fan X., Liu X., Peng L., Ci X. Oridonin sensitizes cisplatin-induced apoptosis via AMPK/Akt/mTOR-dependent autophagosome accumulation in A549 cells. Front. Oncol. 2019;9 doi: 10.3389/fonc.2019.00769.", "ArticleIdList": ["10.3389/fonc.2019.00769", "PMC6702493", "31475112"]}, {"Citation": "Bu H., Liu D., Zhang G., Chen L., Song Z. AMPK/mTOR/ULK1 Axis-Mediated Pathway Participates in Apoptosis and Autophagy Induction by Oridonin in Colon Cancer DLD-1 Cells. OncoTargets Ther. 2020;13:8533. doi: 10.2147/OTT.S262022.", "ArticleIdList": ["10.2147/OTT.S262022", "PMC7457577", "32904616"]}, {"Citation": "Yang Q., Wan Q., Zhang L., Li Y., Zhang P., Li D., Feng C., Yi F., Zhang L., Ding X. Analysis of LncRNA expression in cell differentiation. RNA Biol. 2018;15:413\u2013422. doi: 10.1080/15476286.2018.1441665.", "ArticleIdList": ["10.1080/15476286.2018.1441665", "PMC5927722", "29508657"]}, {"Citation": "Gibb E.A., Brown C.J., Lam W.L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer. 2011;10:38. doi: 10.1186/1476-4598-10-38.", "ArticleIdList": ["10.1186/1476-4598-10-38", "PMC3098824", "21489289"]}, {"Citation": "Nalbantoglu S., Abu-Asab M., Tan M., Zhang X., Cai L., Amri H. Study of clinical survival and gene expression in a sample of pancreatic ductal adenocarcinoma by parsimony phylogenetic analysis. OMICS A J. Integr. Biol. 2016;20:442\u2013447. doi: 10.1089/omi.2016.0059.", "ArticleIdList": ["10.1089/omi.2016.0059", "PMC4968342", "27428255"]}, {"Citation": "Muller P.A.J., Vousden K.H., Norman J.C. p53 and its mutants in tumor cell migration and invasion. J. Cell Biol. 2011;192:209\u2013218. doi: 10.1083/jcb.201009059.", "ArticleIdList": ["10.1083/jcb.201009059", "PMC3172183", "21263025"]}, {"Citation": "Wang S.-P., Wang W.-L., Chang Y.-L., Wu C.-T., Chao Y.-C., Kao S.-H., Yuan A., Lin C.-W., Yang S.-C., Chan W.-K. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 2009;11:694\u2013704. doi: 10.1038/ncb1875.", "ArticleIdList": ["10.1038/ncb1875", "19448627"]}, {"Citation": "Shi D., Gu W. Dual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 2012;3:240\u2013248. doi: 10.1177/1947601912455199.", "ArticleIdList": ["10.1177/1947601912455199", "PMC3494363", "23150757"]}, {"Citation": "Busuttil R.A., Zapparoli G.V., Haupt S., Fennell C., Wong S.Q., Pang J.-M.B., Takeno E.A., Mitchell C., Di Costanzo N., Fox S. Role of p53 in the progression of gastric cancer. Oncotarget. 2014;5:12016. doi: 10.18632/oncotarget.2434.", "ArticleIdList": ["10.18632/oncotarget.2434", "PMC4322971", "25427447"]}, {"Citation": "Fenoglio-Preiser C.M., Wang J., Stemmermann G.N., Noffsinger A. TP53 and gastric carcinoma: A review. Hum. Mutat. 2003;21:258\u2013270. doi: 10.1002/humu.10180.", "ArticleIdList": ["10.1002/humu.10180", "12619111"]}, {"Citation": "Zhu H.-Q., Zhang C., Guo Z.-Y., Yang J.-M., Guo J.-H., Chen C., Yao Q.-H., Liu F., Zhang Q.-W., Gao F.-H. Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma. Cancer Med. 2019;8:5313\u20135326. doi: 10.1002/cam4.2393.", "ArticleIdList": ["10.1002/cam4.2393", "PMC6718599", "31339234"]}, {"Citation": "Jiang J.-H., Pi J., Jin H., Cai J.-Y. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways. J. Cell. Biochem. 2019;120:3736\u20133746. doi: 10.1002/jcb.27654.", "ArticleIdList": ["10.1002/jcb.27654", "30229997"]}, {"Citation": "Vaupel P., Mayer A., H\u00f6ckel M. Methods in Enzymology. Volume 381. Elsevier; Amsterdam, The Netherlands: 2004. Tumor hypoxia and malignant progression; pp. 335\u2013354.", "ArticleIdList": ["15063685"]}, {"Citation": "J\u00f6gi A., Ehinger A., Hartman L., Alkner S. Expression of HIF-1\u03b1 is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. PLoS ONE. 2019;14:e0226150. doi: 10.1371/journal.pone.0226150.", "ArticleIdList": ["10.1371/journal.pone.0226150", "PMC6903737", "31821370"]}, {"Citation": "Yang M.-H., Wu K.-J. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle. 2008;7:2090\u20132096. doi: 10.4161/cc.7.14.6324.", "ArticleIdList": ["10.4161/cc.7.14.6324", "18635960"]}, {"Citation": "Zhang W., Shi X., Peng Y., Wu M., Zhang P., Xie R., Wu Y., Yan Q., Liu S., Wang J. HIF-1\u03b1 promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS ONE. 2015;10:e0129603. doi: 10.1371/journal.pone.0129603.", "ArticleIdList": ["10.1371/journal.pone.0129603", "PMC4461314", "26057751"]}, {"Citation": "Krock B.L., Skuli N., Simon M.C. Hypoxia-induced angiogenesis: Good and evil. Genes Cancer. 2011;2:1117\u20131133. doi: 10.1177/1947601911423654.", "ArticleIdList": ["10.1177/1947601911423654", "PMC3411127", "22866203"]}, {"Citation": "Tsai Y.-P., Wu K.-J. Hypoxia-regulated target genes implicated in tumor metastasis. J. Biomed. Sci. 2012;19:102. doi: 10.1186/1423-0127-19-102.", "ArticleIdList": ["10.1186/1423-0127-19-102", "PMC3541338", "23241400"]}, {"Citation": "Jing X., Yang F., Shao C., Wei K., Xie M., Shen H., Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer. 2019;18:157. doi: 10.1186/s12943-019-1089-9.", "ArticleIdList": ["10.1186/s12943-019-1089-9", "PMC6844052", "31711497"]}, {"Citation": "Guise C.P., Mowday A.M., Ashoorzadeh A., Yuan R., Lin W.-H., Wu D.-H., Smaill J.B., Patterson A.V., Ding K. Bioreductive prodrugs as cancer therapeutics: Targeting tumor hypoxia. Chin. J. Cancer. 2014;33:80. doi: 10.5732/cjc.012.10285.", "ArticleIdList": ["10.5732/cjc.012.10285", "PMC3935009", "23845143"]}, {"Citation": "Marcu L., Olver I. Tirapazamine: From bench to clinical trials. Curr. Clin. Pharmacol. 2006;1:71\u201379. doi: 10.2174/157488406775268192.", "ArticleIdList": ["10.2174/157488406775268192", "18666379"]}, {"Citation": "Phillips R.M., Hendriks H.R., Peters G.J., on Behalf of the EORTC-Pharmacology. Molecular Mechanism Group EO9 (Apaziquone): From the clinic to the laboratory and back again. Br. J. Pharmacol. 2013;168:11\u201318. doi: 10.1111/j.1476-5381.2012.01996.x.", "ArticleIdList": ["10.1111/j.1476-5381.2012.01996.x", "PMC3569998", "22509926"]}, {"Citation": "Chen K., Ye J., Qi L., Liao Y., Li R., Song S., Zhou C., Feng R., Zhai W. Oridonin inhibits hypoxia-induced epithelial-mesenchymal transition and cell migration by the hypoxia-inducible factor-1\u03b1/matrix metallopeptidase-9 signal pathway in gallbladder cancer. Anti Cancer Drugs. 2019;30:925\u2013932. doi: 10.1097/CAD.0000000000000797.", "ArticleIdList": ["10.1097/CAD.0000000000000797", "31517732"]}, {"Citation": "Ding Y., Ding C., Ye N., Liu Z., Wold E.A., Chen H., Wild C., Shen Q., Zhou J. Discovery and development of natural product oridonin-inspired anticancer agents. Eur. J. Med. Chem. 2016;122:102\u2013117. doi: 10.1016/j.ejmech.2016.06.015.", "ArticleIdList": ["10.1016/j.ejmech.2016.06.015", "PMC5003635", "27344488"]}, {"Citation": "Zhou J., Yun E.-J., Chen W., Ding Y., Wu K., Wang B., Ding C., Hernandez E., Santoyo J., Pong R.-C., et al. Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. Cell Death Dis. 2017;8 doi: 10.1038/cddis.2017.121.", "ArticleIdList": ["10.1038/cddis.2017.121", "PMC5386527", "28333136"]}, {"Citation": "Xu J., Yang J., Ran Q., Wang L., Liu J., Wang Z., Wu X., Hua W., Yuan S., Zhang L., et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett. 2008;18:4741\u20134744. doi: 10.1016/j.bmcl.2008.06.097.", "ArticleIdList": ["10.1016/j.bmcl.2008.06.097", "18644718"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "12", "Day": "3"}, {"Year": "2021", "Month": "1", "Day": "5"}, {"Year": "2021", "Month": "1", "Day": "6"}, {"Year": "2021", "Month": "2", "Day": "6", "Hour": "1", "Minute": "2"}, {"Year": "2021", "Month": "2", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "2", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["33546106", "PMC7913218", "10.3390/molecules26040775", "molecules26040775"]}}], "PubmedBookArticle": []}